Linus Gandhi, MD
Internal Medicine · Highland, INNPI 1407836547
Payments from drug & device makers
Across 95 payments — averaging $21.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$365
- AstraZeneca$164
- Amgen$144
- Intuitive Surgical$127
- Lilly USA, LLC$125
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$122
- plus $998 from 21 others
What the payments were for
- Food & beverage$2,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 9 | $365 |
| AstraZeneca | 10 | $164 |
| Amgen(2 entities) | 2 | $144 |
| Intuitive Surgical | 1 | $127 |
| Lilly USA, LLC | 7 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $122 |
| GSK | 8 | $119 |
| Novo Nordisk | 5 | $90 |
| Exact Sciences | 5 | $84 |
| AbbVie | 5 | $83 |
| Pfizer | 4 | $80 |
| Otsuka America Pharmaceutical, Inc. | 4 | $76 |
| Abbott | 3 | $61 |
| Eisai Inc. | 3 | $61 |
| Bayer | 3 | $48 |
| Boston Scientific | 2 | $47 |
| Seqirus USA Inc | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $34 |
| Dexcom, Inc. | 2 | $34 |
| Boehringer Ingelheim | 2 | $28 |
| Edwards Lifesciences | 1 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Philips North America LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Lucid Diagnostics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,045 in reported general payments places this provider in the 80th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 194 | $116,248 |
| OzempicSemaglutide | 57 | $113,663 |
| FarxigaDapagliflozin Propanediol | 54 | $76,213 |
| XareltoRivaroxaban | 48 | $55,991 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 11 | $25,499 |
| LinzessLinaclotide | 26 | $25,447 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $23,401 |
| JardianceEmpagliflozin | 24 | $21,802 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,718 |
| MounjaroTirzepatide | 13 | $19,045 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 58 | $18,054 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 41 | $8,915 |
| CreonLipase/Protease/Amylase | 20 | $7,735 |
| VascepaIcosapent Ethyl | 46 | $7,138 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $5,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $116,248194 claims |
| Novo NordiskOzempic | $90 | $113,66357 claims |
| AstraZenecaFarxiga | $164 | $76,21354 claims |
| Johnson & JohnsonXarelto | $365 | $55,99148 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix, Anoro Ellipta | $119 | $53,622134 claims |
| AbbVieLinzess, Creon | $83 | $33,18246 claims |
| Boehringer IngelheimJardiance | $28 | $21,80224 claims |
| Lilly USA, LLCMounjaro | $125 | $19,04513 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $2,455305 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Highland
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.